- Oops!Something went wrong.Please try again later.
Achiko AG / Key word(s): AGMEGM
2021 Annual General Meeting of Achiko AG: Shareholders adopt all proposals
Zurich, 26 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) ("Achiko" or the "Company") held its Annual General Meeting today at 10:00 CEST in Zurich. Due to the Covid-19 pandemic, this Annual General Meeting was held without physical presence of the shareholders in accordance with art. 27 para. 1 letter b Covid-19-Ordinance 3. Shareholders exercised their shareholder rights through an independent proxy.
Achiko is pleased to announce that all resolutions were duly passed. A total of 19,986,284 shareholder votes of the total share capital of CHF 1,145,592.26, divided into 114,559,226 registered shares with a nominal value of CHF 0.01 each (of which 108,903,900 are registered in the commercial register and 5,655,326 were issued from conditional capital and are not yet registered in the commercial register), were represented by the independent proxy. The board of directors would like to thank all those who exercised their rights as shareholders in this way.
The shareholders approved the annual report, including the corporate governance report, the consolidated financial statements and the statutory financial statements, as well as, in an advisory vote, the compensation report for the financial year 2020. The carry forward of the total balance sheet loss of USD (18,674,296) at year end 2020 was approved.
Allen Wu as chairman of the board of directors as well as Steven Goh and Christophe Laurent as members of the board of directors were confirmed in office for a further term of one year. The shareholders also approved all retrospective and prospective compensations of the board of directors, advisory board and executive committee for the respective compensation periods as proposed by the board of directors.
Shareholders voted to grant discharge to the members of the board of directors, executive committee as well as for all other persons involved in the management of the Company for the financial year 2020. Steven Goh as sole member and chairman of the nomination and remuneration committee, Grant Thornton AG as the auditor for the financial year 2021 and Buis Bürgi AG as independent proxy were approved as well.
About Achiko AG
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.
Further information can be found at www.achiko.com.
If you have any questions regarding the Company, please contact us.
End of ad hoc announcement
SIX Swiss Exchange
EQS News ID:
End of Announcement
EQS Group News Service